Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;54(2):945-9.
doi: 10.1128/AAC.01316-09. Epub 2009 Nov 30.

Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006

Collaborators, Affiliations

Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006

Heather J Adam et al. Antimicrob Agents Chemother. 2010 Feb.

Abstract

We describe the epidemiology of heterogeneously resistant Staphylococcus aureus (hVISA) identified in Canadian hospitals between 1995 and 2006. hVISA isolates were confirmed by the population analysis profiling-area under the curve method. Only 25 hVISA isolates (1.3% of all isolates) were detected. hVISA isolates were more likely to have been health care associated (odds ratio [OR], 5.1; 95% confidence interval [CI], 1.9 to 14.2) and to have been recovered from patients hospitalized in central Canada (OR, 3.0; 95% CI, 1.2 to 7.4). There has been no evidence of vancomycin "MIC creep" in Canadian strains of methicillin (meticillin)-resistant S. aureus, and hVISA strains are currently uncommon.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Alós, J. I., A. Garcia-Cañas, P. Garcia-Hierro, and F. Rodriguez-Salvanés. 2008. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J. Antimicrob. Chemother. 62:773-775. - PubMed
    1. Ariza, J., M. Pujol, J. Cabo, C. Peña, N. Fernández, J. Liñares, J. Ayats, and F. Gudiol. 1999. Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 353:1587-1588. - PubMed
    1. Charles, P. G. P., P. B. Ward, P. D. R. Johnson, B. P. Howden, and M. L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451. - PubMed
    1. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing. nineteenth informational supplement. M100-S19. Clinical Laboratory Standards Institute, Wayne, PA.
    1. Garnier, F., D. Chainier, T. Walsh, A. Karlsson, A. Bolmström, C. Grelaud, M. Mounier, F. Denis, and M.-C. Ploy. 2006. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J. Antimicrob. Chemother. 57:146-149. - PubMed

Publication types

MeSH terms

LinkOut - more resources